AR102345A1 - Uso de paneles del gen mutante del fgfr en la identificación de pacientes de cáncer que serán sensibles al tratamiento con un inhibidor del fgfr - Google Patents
Uso de paneles del gen mutante del fgfr en la identificación de pacientes de cáncer que serán sensibles al tratamiento con un inhibidor del fgfrInfo
- Publication number
- AR102345A1 AR102345A1 ARP150103070A ARP150103070A AR102345A1 AR 102345 A1 AR102345 A1 AR 102345A1 AR P150103070 A ARP150103070 A AR P150103070A AR P150103070 A ARP150103070 A AR P150103070A AR 102345 A1 AR102345 A1 AR 102345A1
- Authority
- AR
- Argentina
- Prior art keywords
- fgfr
- sensitive
- treatment
- cancer patients
- gen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
En la presente descripción se describen métodos para identificar un paciente de cáncer que será sensible al tratamiento con un inhibidor del receptor del factor de crecimiento de fibroblastos (FGFR) y métodos para tratar los pacientes de cáncer. Los métodos implican evaluar una muestra biológica del paciente para detectar la presencia de uno o más mutantes del FGFR de un panel de genes mutantes del FGFR. Los estuches e iniciadores para identificar la presencia de uno o más genes mutantes del FGFR en una muestra biológica se describen, además, en la presente descripción.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056159P | 2014-09-26 | 2014-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102345A1 true AR102345A1 (es) | 2017-02-22 |
Family
ID=54337343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103070A AR102345A1 (es) | 2014-09-26 | 2015-09-24 | Uso de paneles del gen mutante del fgfr en la identificación de pacientes de cáncer que serán sensibles al tratamiento con un inhibidor del fgfr |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20160090633A1 (es) |
| EP (2) | EP4063516A1 (es) |
| JP (3) | JP6766037B2 (es) |
| KR (2) | KR102470456B1 (es) |
| CN (2) | CN113957146A (es) |
| AR (1) | AR102345A1 (es) |
| AU (2) | AU2015321626B2 (es) |
| BR (1) | BR112017006088A2 (es) |
| CA (1) | CA2962075A1 (es) |
| CO (1) | CO2017003528A2 (es) |
| CR (1) | CR20170104A (es) |
| DK (1) | DK3198033T3 (es) |
| EA (1) | EA037920B1 (es) |
| EC (1) | ECSP17025787A (es) |
| ES (1) | ES2912567T3 (es) |
| GT (1) | GT201700059A (es) |
| HR (1) | HRP20220496T1 (es) |
| HU (1) | HUE058219T2 (es) |
| IL (2) | IL251264B (es) |
| JO (1) | JO3681B1 (es) |
| LT (1) | LT3198033T (es) |
| MA (1) | MA40761B1 (es) |
| MX (2) | MX2017003954A (es) |
| MY (1) | MY194567A (es) |
| NI (1) | NI201700035A (es) |
| PH (1) | PH12017500556A1 (es) |
| PL (1) | PL3198033T3 (es) |
| PT (1) | PT3198033T (es) |
| RS (1) | RS63178B1 (es) |
| SG (1) | SG11201702381QA (es) |
| SI (1) | SI3198033T1 (es) |
| SV (1) | SV2017005415A (es) |
| TW (1) | TWI706136B (es) |
| UA (1) | UA122564C2 (es) |
| UY (1) | UY36325A (es) |
| WO (1) | WO2016048833A2 (es) |
| ZA (1) | ZA201702899B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101942148B1 (ko) | 2012-09-27 | 2019-01-24 | 추가이 세이야쿠 가부시키가이샤 | Ｆｇｆｒ３ 융합 유전자 및 그것을 표적으로 하는 의약 |
| JP6731254B2 (ja) | 2014-01-24 | 2020-07-29 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| LT3122358T (lt) | 2014-03-26 | 2021-04-12 | Astex Therapeutics Ltd. | Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) * | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR TREATING MALIGNANT TUMORS |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| MA53655A (fr) * | 2018-09-21 | 2021-12-29 | Janssen Pharmaceutica Nv | Traitement du cholangiocarcinome |
| CA3130460A1 (en) | 2019-03-29 | 2020-10-08 | Anne Elizabeth O'HAGAN | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| JP2022527482A (ja) | 2019-03-29 | 2022-06-02 | ヤンセン ファーマシューティカ エヌ．ベー． | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
| CA3141871A1 (en) * | 2019-05-31 | 2020-12-03 | Qed Therapeutics, Inc. | Methods of treating urinary system cancers |
| CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
| CN115335701A (zh) * | 2019-09-09 | 2022-11-11 | 泽普托生命技术有限责任公司 | 用于检测核酸中基因变异的系统和方法 |
| US20220348662A1 (en) | 2019-09-26 | 2022-11-03 | Janssen Pharmaceutica Nv | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
| AU2021220285A1 (en) | 2020-02-12 | 2022-10-06 | Janssen Pharmaceutica Nv | FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| MX2022012982A (es) * | 2020-04-15 | 2023-03-06 | Alkermes Pharma Ireland Ltd | Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis. |
| CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
| CA3191538A1 (en) | 2020-09-14 | 2022-03-17 | Ademi Elena SANTIAGO-WALKER | Fgfr inhibitor combination therapies |
| CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
| TW202313038A (zh) | 2021-05-19 | 2023-04-01 | 比利時商健生藥品公司 | 用於治療晚期實性瘤之ｆｇｆｒ酪胺酸激酶抑制劑 |
| WO2023064830A1 (en) | 2021-10-12 | 2023-04-20 | Taris Biomedical Llc | Erdafitinib formulations and systems for intravesical administration |
| WO2023159216A1 (en) | 2022-02-18 | 2023-08-24 | Taris Biomedical Llc | Erdafitinib formulations and osmotic systems for intravesical administration |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2447566T3 (es) | 2002-10-01 | 2014-03-12 | Epigenomics Ag | Uso de ácidos nucleicos de PITX2 para mejorar el tratamiento de trastornos proliferativos de células mamarias |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1659175A1 (en) * | 2004-11-18 | 2006-05-24 | Institut Curie | Alterations in seborrheic keratoses and their applications |
| CN101218228A (zh) | 2005-05-23 | 2008-07-09 | 诺瓦提斯公司 | 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式 |
| US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| JP2009523410A (ja) | 2005-12-08 | 2009-06-25 | ノバルティス アクチエンゲゼルシャフト | 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果 |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
| CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释－缓释渗透泵制剂 |
| SG2014010276A (en) | 2011-08-18 | 2014-03-28 | Nestec Sa | Compositions and methods for detecting allelic variants |
| EP2761300A4 (en) * | 2011-09-27 | 2015-12-02 | Univ Michigan | FUSIONS OF RECURRENT GENES IN BREAST CANCER |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013088191A1 (en) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| KR102032007B1 (ko) * | 2012-02-28 | 2019-10-14 | 아스텔라스세이야쿠 가부시키가이샤 | 질소 함유 방향족 헤테로환 화합물 |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| WO2014007369A1 (ja) * | 2012-07-05 | 2014-01-09 | 独立行政法人国立がん研究センター | Ｆｇｆｒ２融合遺伝子 |
| WO2014018673A2 (en) * | 2012-07-24 | 2014-01-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| KR101942148B1 (ko) * | 2012-09-27 | 2019-01-24 | 추가이 세이야쿠 가부시키가이샤 | Ｆｇｆｒ３ 융합 유전자 및 그것을 표적으로 하는 의약 |
| WO2014071419A2 (en) * | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EP2945652B1 (en) * | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
-
2015
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active IP Right Grant
- 2015-09-18 KR KR1020227040649A patent/KR20220162823A/ko not_active Application Discontinuation
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/en active Application Filing
- 2015-09-18 MX MX2017003954A patent/MX2017003954A/es unknown
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 CN CN202111247854.6A patent/CN113957146A/zh active Pending
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/en active Pending
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 CA CA2962075A patent/CA2962075A1/en active Pending
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/en active Active
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 BR BR112017006088A patent/BR112017006088A2/pt active Search and Examination
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US20190078166A1/en active Pending
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633A1/en active Pending
-
2022
- 2022-03-23 IL IL291633A patent/IL291633A/en unknown
- 2022-03-30 JP JP2022056709A patent/JP2022109910A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102345A1 (es) | Uso de paneles del gen mutante del fgfr en la identificación de pacientes de cáncer que serán sensibles al tratamiento con un inhibidor del fgfr | |
| CY1124879T1 (el) | Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου | |
| CO7151491A2 (es) | Método para la identificación del origen de un cancer de origen primario desconocido | |
| SV2017005577A (es) | Metodos para diagnosticar y tratar el cancer | |
| MX2020004247A (es) | Acidos nucleicos libres de celulas para el analisis del microbioma humano y componentes del mismo. | |
| CL2019002438A1 (es) | Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. | |
| PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| BR112014011925A2 (pt) | mutações no receptor notch humano e seu uso | |
| TW201614237A (en) | Markers for identifying patients responsive to anti-PD-L1 antibody therapy | |
| MX2019007894A (es) | Composiciones y metodos para detectar el adn tumoral circulante. | |
| SV2017005459A (es) | Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr | |
| BR112015020054A2 (pt) | Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa | |
| BR102015015096A2 (pt) | método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna | |
| PL408727A1 (pl) | Zestaw diagnostyczny i sposób jednoczesnego wykrywania mutacji w obrębie genu NF1 dla grupy pacjentów z podejrzeniem choroby Recklinghausena | |
| UA92246U (ru) | Спектрофотометрический способ количественного определения зопиклона | |
| BR112017012553A2 (pt) | método de tratamento de um paciente que sofre de um câncer, método para o diagnóstico de um câncer, método para o prognóstico de um paciente que sofre de câncer, método para determinar se um paciente com um câncer e método para otimizar a eficácia terapêutica de uma terapia anticâncer |